{
    "clinical_study": {
        "@rank": "1713", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the safety of human botulism immune globulin (BIG) in patients\n      with infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and\n      anaphylaxis).\n\n      II. Assess the efficacy of BIG in these patients by monitoring disease severity, incidence\n      of complications (respiratory arrest, aspiration, pneumonia, etc.), and length of hospital\n      stay."
        }, 
        "brief_title": "Study of Human Botulism Immunoglobulin in Infants With Botulism", 
        "condition": [
            "Infant Botulism", 
            "Botulism"
        ], 
        "condition_browse": {
            "mesh_term": "Botulism"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is an open label, multicenter study. Patients should begin therapy\n      within 72 hours of hospital admission, but may receive human botulism immunoglobulin (BIG)\n      in certain circumstances after 72 hours.  Patients receive (BIG) IV.  Patients are monitored\n      for side effects, disease severity, complications, and length of hospital stay.\n\n      Patients are followed at 2 weeks after treatment, then every 4 weeks for 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Clinical diagnosis of infant botulism in previously healthy infant\n\n          -  Bulbar palsies\n\n          -  Constipated Lethargy\n\n          -  Diminished head control\n\n          -  Poor feeding\n\n          -  Generalized weakness and hypotonia\n\n          -  Weak cry\n\n          -  Afebrile (unless secondary infection present)\n\n          -  Subacute to acute onset\n\n          -  Normal electrolytes\n\n          -  Any patient eligible provided no treatment available for life-threatening condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "1 Year", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004401", 
            "org_study_id": "199/13253", 
            "secondary_id": "CDHS-FDU000476"
        }, 
        "intervention": {
            "intervention_name": "botulism immune globulin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "keyword": [
            "bacterial infection", 
            "clostridium infection", 
            "immunologic disorders and infectious disorders", 
            "infant botulism", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "contact": {
                "last_name": "Stephen S. Arnon", 
                "phone": "510-540-2646"
            }, 
            "facility": {
                "address": {
                    "city": "Berkeley", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94704-1011"
                }, 
                "name": "California Department of Health Services"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "California Department of Health Services", 
            "last_name": "Stephen S. Arnon", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004401"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "California Department of Health Services", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "January 1998", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2000"
    }, 
    "geocoordinates": {
        "California Department of Health Services": "37.872 -122.273"
    }
}